

*a 1* 5. (Amended) An application according to claim 1, wherein the pharmaceutical composition further contains a protease inhibitor, and as an option further protease inhibitors different therefrom.

*a 2* 8. (Amended) A pharmaceutical composition according to claim 6, wherein the drug components drug component b) is a pyrimidin nucleoside analogue, preferably 3'-azido-3'-desoxythymidine, and/or the drug component c) is 3TC, and/or the drug component d) is provided in a conclusive manner.

9. (Amended) A pharmaceutical composition according to claim 6, wherein the drug components b) to e) are part of a first package component, and the drug component a) is part of a second package component.

10. (Amended) A package component according to claim 6, containing the drug component a).

11. (Amended) A method for treating virus infections with retrovirus, in particular lentivirus, for instance HIV, wherein the pharmaceutical composition according to claim 6 is administered to a human body or to the body of a lower warm-blooded animal attacked by the infection.

14. (Amended) A method according to claim 12, wherein the drug components b) to e) are administered continuously and the drug component a) once or several times in time intervals with breaks.

15. (Amended) A method according to claim 12 , wherein the drug component b) is a pyrimidin nucleoside analogue, preferably 3'-azido-3'-desoxythymidine, and/or the drug component c) is 3TC, and/or the drug component d) is provided in a conclusive manner.

18. (Amended) An application, pharmaceutical composition, package component or method according to claim 1, wherein the monoclonal antibody is CMY-2, available from hybridom cells according to deposit DSM ACC2353, or the clone ANC28.1/5D10, or a preferably humanized or human-tolerated variant of the clone ANC28.1/ 5D10.